TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04074070

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Ultrasound examination of joints, tendons and entheses.

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Ultrasound examination of joints, tendons and entheses.

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Ultrasound examination of joints, tendons and entheses.
Study: NCT01692106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Per Oral Endoscopic Myotomy (POEM)
Description: lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
Study: NCT04430608

Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom G6
Description: The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC.
Study: NCT04122989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MS-SUPPORT
Description: MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
Study: NCT01861704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyric
Description: Extended wear hearing instrument

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyric2
Description: Extended wear hearing instrument
Study: NCT04033081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CivaSheet
Description: Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
Study: NCT04420832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Se above

Intervention type: OTHER
Group type: OTHER
Intervention: Non-surgical treatment
Description: See above
Study: NCT03435484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm B
Description: Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
Study: NCT02280304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inner Resources for Veterans (IRV)
Description: Mindfulness and breath-focused mantra therapy which uses techniques that encourage present moment attention for the purpose of improving self-monitoring and self-regulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Essential Skills therapy
Description: This active comparator is adapted from a therapy utilized at multiple VAs as a psychoeducational AND symptom management treatment for PTSD. In it, participants learn about mTBI and PTSD symptoms and coping information for PTSD.
Study: NCT01606800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2b
Description: Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2b
Description: Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Ribavirin 200 mg capsules administered orally daily based on weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Ribavirin 200 mg capsules administered orally daily based on weight
Study: NCT06120998

Intervention type: PROCEDURE
Intervention: Arthroscopic rotator cuff repair
Description: All patients were placed in a semi-sitting position. Initially, a posterior portal was established to explore the inside of the joint, a lateral portal was created for the removal of subacromial bursa, and an additional anterior portal was created for repairing the tendons. Measurements were taken to determine the extent of rotator cuff damage, including its anterior-posterior and medial-lateral dimensions. In cases where complete repair was possible, a single-row or double-row repair technique was used depending on the degree of tendon damage. For situations where complete repair was not feasible, partial repair was performed. If the tendon could be stretched after relaxation, it was repaired to an anatomical position near the bone bed with the assistance of acellular dermal reinforcement. However, if the tendon lacked elasticity and was fully retracted upon relaxation, acellular dermis was used to bridge the tendon back to the anatomical position.
Study: NCT02036697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 4.5
Description: Bupivacaine hyperbaric, 4.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 9
Description: Bupivacaine hyperbaric, 9 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 150 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine 150 mcg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 15 mcg
Study: NCT02943317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - VS-6063
Description: Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - Avelumab
Description: Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
Study: NCT04381416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEAD treatment
Description: up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEAD treatment
Description: up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
Study: NCT02035605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-AT3SC
Description: Ascending doses of ALN-AT3SC by subcutaneous (sc) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT01074788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind body therapy
Description: mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
Study: NCT01477255

Intervention type: BEHAVIORAL
Intervention: iPad
Description: The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.

Intervention type: BEHAVIORAL
Intervention: iPad
Description: The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
Study: NCT02987192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pen type 27 gauge needles
Description: minimally invasive group patients will receive pen type 27 gauge needles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cutting type 22 gauge needles
Description: traditional group patients will receive cutting type 22 gauge needles.
Study: NCT03955575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 6 MG/ML
Description: Liraglutide as injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: 3 x 625 miligram 2 times a day.
Study: NCT00629096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow cells
Description: Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
Study: NCT05150912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: strching neck

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: strching neck
Study: NCT01599793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI
Study: NCT04522466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ).
Study: NCT03285542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DERMABOND
Description: DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Staples
Description: staples for skin closure
Study: NCT00746655

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcatheter Arterial Chemoembolization (TACE)
Description: . Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
Study: NCT02115828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Study: NCT03036176

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Play-based family centered stimulation
Description: Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
Study: NCT00634075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-fatty acids (Omegaven)
Description: The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
Study: NCT02129595

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
Study: NCT02036697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15 mcg
Study: NCT01135420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring (TM) with Motivational Interviewing
Description: Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
Study: NCT01354340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limicol
Description: 3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limicol
Description: 6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
Study: NCT03093948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic post-conditioning
Description: Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
Study: NCT03948802

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukine 33 test in blood plasma
Description: ELISA test for Interleukin 33

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukine 33 test in blood plasma
Description: ELISA test for Interleukin 33
Study: NCT00581048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural source d-α-tocopheryl acetate
Description: 1500 units daily for 16 weeks
Study: NCT01354340

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
Study: NCT00126191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
Study: NCT02820844

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Benefit Scale (TBS)
Description: The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820.
Study: NCT02227030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB 722 CL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB 722 CL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB 722 CL tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study: NCT03045588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise and diet intervention
Description: Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercise and diet intervention
Description: Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
Study: NCT01739608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to screening
Description: Invitation to screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation to screening
Description: Invitation to screening
Study: NCT00792311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tsui test
Description: The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
Study: NCT00466947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection,3 doses
Study: NCT01525303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment for Chronic Headache- Exercise Version
Description: This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment for Chronic Headache- Exercise Version
Description: This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
Study: NCT01976169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991 and T-DM1
Description: The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)
Study: NCT00466947

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' DTPa-IPV/Hib vaccine
Description: Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' DTPa-IPV/Hib vaccine
Description: Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
Study: NCT01822769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation
Description: See Arm Description

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: See Arm Description
Study: NCT00126191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)